Johnson & Johnson reports Q1 2026 results, raises 2026 outlook | lifestyle.brickvest.com

LifestyleSaturday, September 19, 20264h agoWIRE COPY

Johnson & Johnson reported a strong Q1 2026, continuing an expected year of accelerated growth, driven by strength in Oncology, Immunology, and Neuroscience, with notable approvals including ICOTYDE for plaque psoriasis in the U.S. and VARIPULSE Pro in Europe, as well as ongoing FDA activity around TECNIS, TECVAYLI/DARZALEX FASPRO, and other initiatives. The company highlighted solid sales growth in Innovative Medicine, supported by net acquisitions/divestitures and a favorable 12-month outlook, though some impact from STELARA alongside other portfolio dynamics moderated gains.

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook | lifestyle.brickvest.com # Johnson & Johnson reports Q1 2026 results, raises 2026 outlook Business Wire Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2026. “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the potential to transform patient outcomes and create sustainable, long-term value for shareholders.” Overall financial results Q1 ($ in Millions, except EPS) 2026 2025 % Change Reported Sales $24,062 $21,893 9.9% Net Earnings $5,235 $10,999 -52.4% EPS (diluted) $2.14 $4.54 -52.9% Q1 Non-GAAP* ($ in Millions, except EPS) 2026 2025 % Change Operational Sales 1,2 6.4% Adjusted Operational Sales 1,3 5.3% Adjusted Net Earnings 1,4 $6,614 $6,706 -1.4% Adjusted EPS (diluted) 1,4 $2.70 $2.77 -2.5% Free Cash Flow 5,6 ~$1,500 $3,379 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translat…

read it at lifestyle.brickvest.com

the newsroom’s read

SKIPscore of 100

Corporate earnings reports are barred as traditional financial news lacking tokenistic novelty under standard desk rules.

Launch this story

Proof sheet

name: Johnson and Johnson
ticker: $JNJQ1
description: Johnson and Johnson reports strong Q1 2026 results and raises outlook, driven by oncology and new drug approvals, as reported by Lifestyle.

More from Business

section

BUSINESS90LAUNCH

BREAKING: OpenAI expects to burn $280 billion by 2030, and have deeply negative cash flows, per FT

@unusual_whales3h ago

BREAKING: OpenAI expects to burn $280 billion by 2030, and have deeply negative cash flows, per FT

the newsroomMassive business and tech news with high shareability, detailing staggering cash burn projections reported by @unusual_whales.

Launch this story

BUSINESS40WATCH

The FBI believes women pretending to be tradwives are targeting Immigration and Customs Enforcement officers in order to dox them, per The Guardian

@unusual_whales3h ago

The FBI believes women pretending to be tradwives are targeting Immigration and Customs Enforcement officers in order to dox them, per The Guardian

the newsroomBizarre FBI warning about internet subcultures targeting officials, but too niche and thin for an immediate launch.

BUSINESS82LAUNCH

Nvidia-backed AI cloud firm Nscale reveals revenue surge in US IPO filing - CNA

Channelnewsasia4h ago

Nscale, a Nvidia-backed UK cloud provider, reported a 1,252% revenue surge to $140.6 million for H1 2026 while swinging to a net loss of $1.02 billion, as it files for a multibillion-dollar NYSE listing aiming around a $30 billion valuation. The company, which has over $100 billion in contracted revenue and large deals like Anthropics’ $45 billion spend, plans to issue new shares and recently raised $3.1 billion in convertible bonds; its top customer accounted for about 52% of H1 2026 revenue, with expectations of Microsoft and Anthropic as future major customers.

the newsroomA massive Nvidia-backed AI cloud provider filing for a multi-billion dollar IPO makes for a high-impact, shareable market narrative.

Launch this story

BUSINESS55WATCH

S&P 500, Nasdaq advance, turning the page on a tumultuous week | The Straits Times

Straitstimes4h ago

- Wall Street ended a volatile week with the S&P 500 little changed and the Nasdaq rising, as yields stayed above 5% and oil remained over $100 a barrel, fueling ongoing inflation concerns. - Markets priced in a roughly 55% chance of another Fed rate hike in October, while global central banks continued tightening, and a semiconductor rally helped the Nasdaq while the Dow posted a weekly decline.

the newsroomA solid broad market end-of-week wrap, but derivative of standard macroeconomic reporting.

BUSINESS60WATCH

Wall St slips as higher Treasury yields weigh on sentiment | MarketScreener Australia

Au4h ago

- U.S. stocks fell on Friday as higher Treasury yields, shifting oil prices, and ongoing expectations of a Federal Reserve rate hike pressured sentiment, with the S&P 500, Dow, and Nasdaq all edging lower during a volatile triple-witching session. - The 10-year Treasury yield rose to about 5.00%, while investors weighed AI demand concerns and comments from market strategists ahead of upcoming earnings and a potential US-China meeting, with materials leading the day’s losses.

the newsroomStandard market wrap reporting on Treasury yields and triple-witching, lacking a single standout token anchor besides general macro sentiment.